TANG-2018
Regimen
- Experimental
- Nedaplatin 100 mg/m² q3w ×3 concurrent with IMRT 70 Gy
- Control
- Cisplatin 100 mg/m² q3w ×3 concurrent with IMRT 70 Gy
Population
Stage II-IVB NPC (M0), Sun Yat-sen University Cancer Center, IMRT era
Key finding
Established nedaplatin as a non-inferior alternative to cisplatin as the concurrent sensitiser in CCRT for NPC. Nedaplatin significantly reduced grade 3-4 nausea (2% vs 9%), vomiting (6% vs 18%), anorexia (13% vs 27%), and late auditory toxicity compared with cisplatin. This provides an evidence-based option for patients with cisplatin-related renal or auditory risk. The trial was conducted entirely at SYSU — a single-centre registration trial validating a domestic platinum compound.
Source: PMID 29501366